Literature DB >> 22505018

Multimodal interventional molecular imaging of tumor margins and distant metastases by targeting αvβ3 integrin.

Anton Bunschoten1, Tessa Buckle, Nils L Visser, Joeri Kuil, Hushan Yuan, Lee Josephson, Alexander L Vahrmeijer, Fijs W B van Leeuwen.   

Abstract

α(v)β(3) integrin is involved in (tumor-induced) angiogenesis and is a promising candidate for the specific visualization of both primary tumors and of their distant metastases. Combination of radioactive and fluorescent imaging labels in a single multimodal, or rather hybrid, RGD-based imaging agent enables integration of pre-, intra-, and postoperative angiogenesis imaging. A hybrid imaging agent targeting the α(v)β(3) integrin--(111)In-MSAP-RGD (MSAP = multifunctional single-attachment-point reagent), which contains a targeting moiety, a pentetic acid (DTPA) chelate, and a cyanine dye--was evaluated for its potential value in combined lesion detection and interventional molecular imaging in a 4T1 mouse breast cancer model. SPECT/CT and fluorescence imaging were used to visualize the tumor in vivo. Tracer distribution was evaluated ex vivo down to the microscopic level. The properties of (111)In-MSAP-RGD were compared with those of (111)In-DTPA-RGD. Biodistribution studies revealed a prolonged retention and increased tumor accumulation of (111)In-MSAP-RGD relative to (111)In-DTPA-RGD. With (111)In-MSAP-RGD, identical features could be visualized preoperatively (SPECT/CT) and intraoperatively (fluorescence imaging). As well as the primary tumor, (111)In-MSAP-RGD also enabled detection and accurate excision of distant metastases in the head and neck region of the mice. Therefore, the hybrid RGD derivative (111)In-MSAP-RGD shows potential in preoperative planning and fluorescence-based surgical intervention.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22505018      PMCID: PMC3498954          DOI: 10.1002/cbic.201200034

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  42 in total

1.  Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe.

Authors:  Chun Li; Wei Wang; Qingping Wu; Shi Ke; Jessica Houston; Eva Sevick-Muraca; Liang Dong; Diana Chow; Chusilp Charnsangavej; Juri G Gelovani
Journal:  Nucl Med Biol       Date:  2006-04       Impact factor: 2.408

Review 2.  (Non-targeted) radioactive/fluorescent nanoparticles and their potential in combined pre- and intraoperative imaging during sentinel lymph node resection.

Authors:  Tessa Buckle; Patrick T K Chin; Fijs W B van Leeuwen
Journal:  Nanotechnology       Date:  2010-11-10       Impact factor: 3.874

3.  Tracer-cocktail injections for combined pre- and intraoperative multimodal imaging of lymph nodes in a spontaneous mouse prostate tumor model.

Authors:  Anne C van Leeuwen; Tessa Buckle; Gavin Bendle; Lenka Vermeeren; Renato Valdés Olmos; Henk G van de Poel; Fijs W B van Leeuwen
Journal:  J Biomed Opt       Date:  2011 Jan-Feb       Impact factor: 3.170

4.  Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy.

Authors:  P M van Hagen; W A Breeman; H F Bernard; M Schaar; C M Mooij; A Srinivasan; M A Schmidt; E P Krenning; M de Jong
Journal:  Int J Cancer       Date:  2000-08-20       Impact factor: 7.396

Review 5.  Interventional molecular imaging.

Authors:  Xiaoming Yang
Journal:  Radiology       Date:  2010-03       Impact factor: 11.105

6.  Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer.

Authors:  Henk G van der Poel; Tessa Buckle; Oscar R Brouwer; Renato A Valdés Olmos; Fijs W B van Leeuwen
Journal:  Eur Urol       Date:  2011-04-01       Impact factor: 20.096

7.  Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay.

Authors:  Nikki Parker; Mary Jo Turk; Elaine Westrick; Jeffrey D Lewis; Philip S Low; Christopher P Leamon
Journal:  Anal Biochem       Date:  2005-03-15       Impact factor: 3.365

Review 8.  Microenvironmental and cellular consequences of altered blood flow in tumours.

Authors:  N Raghunand; R A Gatenby; R J Gillies
Journal:  Br J Radiol       Date:  2003       Impact factor: 3.039

9.  Divergent oriented synthesis for the design of reagents for protein conjugation.

Authors:  Elisabeth Garanger; Joseph Blois; Scott A Hilderbrand; Fangwei Shao; Lee Josephson
Journal:  J Comb Chem       Date:  2010 Jan-Feb

10.  Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.

Authors:  Lakshmi Sampath; Sunkuk Kwon; Shi Ke; Wei Wang; Rachel Schiff; Michel E Mawad; Eva M Sevick-Muraca
Journal:  J Nucl Med       Date:  2007-09       Impact factor: 10.057

View more
  13 in total

Review 1.  Molecular imaging agents for SPECT (and SPECT/CT).

Authors:  Gopinath Gnanasegaran; James R Ballinger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-07       Impact factor: 9.236

2.  Analysis of expression of membrane-bound tumor markers in ductal carcinoma in situ of the breast: paving the way for molecular imaging.

Authors:  Jeroen F Vermeulen; Elsken van der Wall; Arjen J Witkamp; Paul J van Diest
Journal:  Cell Oncol (Dordr)       Date:  2013-06-07       Impact factor: 6.730

3.  Near-infrared fluorescence imaging of both colorectal cancer and ureters using a low-dose integrin targeted probe.

Authors:  Floris P R Verbeek; Joost R van der Vorst; Quirijn R J G Tummers; Martin C Boonstra; Karien E de Rooij; Clemens W G M Löwik; A Rob P M Valentijn; Cornelis J H van de Velde; Hak Soo Choi; John V Frangioni; Alexander L Vahrmeijer
Journal:  Ann Surg Oncol       Date:  2014-02-11       Impact factor: 5.344

4.  Use of a single hybrid imaging agent for integration of target validation with in vivo and ex vivo imaging of mouse tumor lesions resembling human DCIS.

Authors:  Tessa Buckle; Joeri Kuil; Nynke S van den Berg; Anton Bunschoten; Hildo J Lamb; Hushan Yuan; Lee Josephson; Jos Jonkers; Alexander D Borowsky; Fijs W B van Leeuwen
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

5.  uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery.

Authors:  Martin C Boonstra; Pieter B A A van Driel; Danny M van Willigen; Marieke A Stammes; Hendrica A J M Prevoo; Quirijn R J G Tummers; Andrew P Mazar; Freek J Beekman; Peter J K Kuppen; Cornelis J H van de Velde; Clemens W G M Löwik; John V Frangioni; Fijs W B van Leeuwen; Cornelis F M Sier; Alexander L Vahrmeijer
Journal:  Oncotarget       Date:  2015-06-10

6.  U-SPECT-BioFluo: an integrated radionuclide, bioluminescence, and fluorescence imaging platform.

Authors:  Matthias N van Oosterom; Rob Kreuger; Tessa Buckle; Wendy A Mahn; Anton Bunschoten; Lee Josephson; Fijs Wb van Leeuwen; Freek J Beekman
Journal:  EJNMMI Res       Date:  2014-10-11       Impact factor: 3.138

Review 7.  Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins.

Authors:  Martin C Boonstra; Susanna W L de Geus; Hendrica A J M Prevoo; Lukas J A C Hawinkels; Cornelis J H van de Velde; Peter J K Kuppen; Alexander L Vahrmeijer; Cornelis F M Sier
Journal:  Biomark Cancer       Date:  2016-09-27

Review 8.  Hybrid intraoperative imaging techniques in radioguided surgery: present clinical applications and future outlook.

Authors:  S L Bugby; J E Lees; A C Perkins
Journal:  Clin Transl Imaging       Date:  2017-06-27

9.  Heat-induced-radiolabeling and click chemistry: A powerful combination for generating multifunctional nanomaterials.

Authors:  Hushan Yuan; Moses Q Wilks; Georges El Fakhri; Marc D Normandin; Charalambos Kaittanis; Lee Josephson
Journal:  PLoS One       Date:  2017-02-22       Impact factor: 3.240

Review 10.  Stromal Targets for Fluorescent-Guided Oncologic Surgery.

Authors:  Martin C Boonstra; Jai Prakash; Cornelis J H Van De Velde; Wilma E Mesker; Peter J K Kuppen; Alexander L Vahrmeijer; Cornelis F M Sier
Journal:  Front Oncol       Date:  2015-11-20       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.